Will Roche's Perseverance pay off?
Giredestrant will soon become the first oral SERD to yield first-line data.
Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
ASCO-GU – some backing for Pfizer's EZH2 plan
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
